IMMX — Immix Biopharma Balance Sheet
0.000.00%
Last trade - 00:00
- $54.94m
- $25.34m
- 31
- 21
- 27
- 16
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.734 | 0.391 | 17.6 | 13.4 | 17.5 |
Net Total Receivables | 0.176 | 0.127 | 0.026 | 0.256 | 1.17 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 0.933 | 0.532 | 18.2 | 14.9 | 19.8 |
Net Property, Plant And Equipment | 0.01 | 0.007 | 0.006 | 0.004 | 0.05 |
Other Long Term Assets | |||||
Total Assets | 0.943 | 0.54 | 18.2 | 14.9 | 19.9 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.59 | 5.27 | 0.202 | 1.27 | 3.72 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 4.59 | 5.27 | 0.202 | 1.75 | 3.52 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | -3.65 | -4.73 | 18 | 13.2 | 16.4 |
Total Liabilities & Shareholders' Equity | 0.943 | 0.54 | 18.2 | 14.9 | 19.9 |
Total Common Shares Outstanding |